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Background
KAE609, a spiroindolone, represents a new class of potent,
fast-acting, schizonticidal antimalarials. Antimalarial com-
bination treatment is recommended to minimize the
potential emergence of resistance on clinical use. Pipera-
quine (PPQ) is a marketed, long acting antimalarial used
in combination with short-acting artemisinins. As both
KAE609 and PPQ are CYP3A4 substrates and inhibitors
based on in vitro or clinical reports, a two way interaction
was hypothesized. The potential for both agents to affect
the QT interval was also assessed.
Materials and methods
This was an open-label, parallel-group, single-dose study
in healthy volunteers randomized to four parallel dosing
arms for five cohorts (2:2:2:2:1) of 75 mg KAE609 plus 320
mg PPQ, 25 mg KAE609 plus 1280 mg PPQ, 25 mg
KAE609 alone, 320 mg PPQ alone or 1280 mg PPQ alone.
Triplicate ECGs were done over the first 24 hours after
dosing, with single ECGs at other time points. Routine
safety and pharmacokinetic assessments were carried out
up to 89 and 61 days respectively.
Results
Of the 110 healthy male subjects recruited, 99 completed
the study. Co-administration of PPQ had no overall effect
on exposure to KAE609, although 1280 mg PPQ decreased
KAE609 Cmax by 17%. 25 mg KAE609 plus 1280 mg PPQ
showed a 32% increase, while 75 mg KAE609 plus 320 mg
PPQ showed a 14% reduction in PPQ AUCinf; the reasons
for this are unclear. Mean changes from baseline in QTcF
and QTcB with PPQ were consistent with the known
effects of PPQ on QTc interval. PPQ but not KAE609
exposure correlated with QTc increase. Also, KAE609 did
not affect the PPQ exposure-QTc relationship. The QTcF
effect for PPQ (mean maximal change from baseline LS
estimate of difference 7.47 msec; 90% CI 3.55, 11.4) was
consistent with a positive thorough QT study (ICHE14,
mean maximal effect ≥5 msec and upper 95% CI ≥10
msec). No subject had a QTcF or QTcB >500 msec. Most
adverse events (AEs) reported were mild; upper respiratory
tract infections, headache, diarrhea and oropharyngeal pain
were most commonly reported. There were no deaths, ser-
ious AEs or severe AEs.
Conclusions
PPQ and KAE609 co-administration had no clinically rele-
vant effect on exposure to either agent. KAE609 had no
effect and did not potentiate the known effects of PPQ on
cardiac conduction. Both drugs administered alone or in
combination were well tolerated.
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